|
Antivirol manufacture involves several steps to introduce energy information
into liquid crystal water molecules prior to ingestion. Water appears
to be able to store information carried on various energy fields such as
electric, magnetic, photonic, sonic. This forms part of the basis
of Homeopathy (succussion). One of these steps (UV irradiation of
the water while in an open state) is based on an innovative method of inactivating
bloodborne viruses using ultraviolet irradiation called UBI therapy.
This process has shown impressive clinical results in treating hepatitis,
HIV, and other currently untreatable viruses. UBI offers a potential
breakthrough in the treatment of viral diseases and bacteria, and is nontoxic,
uses no drugs, and even has FDA certification, and thus is available now
for use. Antivirol has the advantage that it is orally or topically ingested,
does not involve intravenous blood, is more safe, convenient, effective
and economical, and like most homeopathic remedies can store the specific
antimicrobial information for several months.
History: Ultraviolet blood irradiation first evolved in
the early I930s as a means to treat persons afflicted with the poliovirus
which was causing considerable anguish and fear similar to the advent of
the HIV in the 1980s and continuing. Then in the 1950s the
Salk vaccine wiped out polio in the U.S. and, as a result of this fact
and other reasons, this process fell in disuse. This process has now been
developed to new levels by Antivirol scientists using vastly improved technical
and medical tools.
Researchers in Russia have used this process to treat HIV with impressive
results Improvements have been noted in HIV-infected patients
in terms of CD4 T cells, leucocytes, etc. Ultraviolet blood irradiation
therapy (UBIT) is currently FDA approved (and the treatment of choice)
for cutaneous T-cell lymphoma (CTCL) (Taylor & Gasparro, 1992). Using
a technique based on extensive historical experience with PUVA therapy
in dermatology, Edelson and his group at Yale have developed a sophisticated
UBlT method involving pretreatment with psolaren, extracorporeal leukopheresis,
UV-A irradiation of the white blood cell fraction, and reinfusion (Edelson,
1987). This process has been given the name"photopheresis." In the
current listings of world medical literature at the National Library of
Medicine on UBIT (excluding photopheresis) there are over 100 articles,
and all of these are in the Soviet literature. Like Knott, it appears that
the Soviets have applied UBIT to a wide variety of conditions, but only
over the past two decades (Arutiunov, 1988).
Currently: UBIT is now available and FDA certified
for use in the U.S and is being further researched under a CRADA
(Cooperative Research and Development Agreement) with the Lawrence Livermore
National Laboratories of Berkeley, California. Steps are now being
taken to arrange research protocols at several major university medical
research centers on both the East and West coasts of the U.S. Focus
will be on treatment of HIV, hepatitis, malaria and those viruses immune
to current antibiotics.
Photopheresis is currently undergoing clinical trials at centers around
the county for the treatment of systemic sclerosis, multiple sclerosis,
rheumatoid arthritis, autoimmune insulin-dependent diabetes, systemic lupus
erythematosis, myasthenia gravis, graft versus host disease, pemphigus
vulgaris, and HIV associated disease (Edelson, 1991; Bisaccia et al, 1990).
The major drawbacks to photopheresis are that the technique is cumbersome
and costly; a single treatment occupies patient and skilled technician
for upwards of five hours. Historically, the Knott technique of UBlT
(Knott, 1948) was applied extensively and with excellent results during
the 1930s, 40s, and 50s for the treatment of a wide variety of conditions.
There are published reports on its use in bacterial diseases, including
septicemias, pneumonias, peritonitis, wound infections; viral infections
including acute and chronic hepatitis, atypical pneumonias, poliomyelitis,
encephalitis, mumps, measles, mononucleosis, and herpes; circulatory conditions
including thrombophlebitis, peripheral vascular arsenal disease, and diabetic
ulcer; overwhelming toxemias, non-healing wounds and delayed union of fractures,
rheumatoid arthritis, and a number of others (Barger & Knott, 1950).
Mechanism: Ultraviolet blood irradiation therapy (UBIT),
or intravenous ultraviolet, raises the resistance of the host and is therefore
able to control many disease processes. A fundamental effect of ultraviolet
blood irradiation is to "energize" the biochemical and physiological defenses
of the body by the introduction of ultraviolet energy into fluids which
are later ingested into the bloodstream. Some of the success may,
in part, be effective by producing small amounts of ozone, however
in Silver-Max, a greater effect seems to be due to unique photo-activation
of water molecules in the presence of special magnetic and electric fields
and their unique frequencies. There are many effects of ultraviolet
light on water, colloids and blood components that may be involved in clinical
effectiveness. The interaction of various wavelengths of ultraviolet with
living tissues is complex and constitutes an entire area of specialization
for photobiologists (Coohill, 1991).
Results: The efficacy of this method is attested to by
the remarkable and consistent recovery of patients with a wide variety
of unrelated diseases. In addition, UBI and Silver-Max have never
caused any adverse side effects nor have they ever worsened any disease
in any patient, regardless of age group, race or sex and regardless of
the number of blood irradiation treatments administered. There have
not been any complications related to UBlT during long-term followup.
Clinical improvement occurred on an average of 19.2 days after institution
of blood irradiation therapy. Sixty percent of the patients were considered
clinically recovered and able to return to their occupation in two weeks
or less. In one study, cyanosis was cleared in hypoxic patients and
increases in oxygenation were measured. Clinical Results of Ultraviolet
Blood Irradiation in Treating HlV-Positive Persons were obtained by using
the PCR Diagnostic test (Polymerase Change Reaction) which accurately determines
change in viral activity in 1995. Each treatment of UBI reduced PCR by
50%-75%. This is considered a very significant reduction.
Viruses: Viral illnesses, given their comparative resistance
to chemotherapeutic control, have emerged over the past several decades
as a major challenge for medicine. In addition, immune system dysfunctions
are increasingly recognized as playing a major"host factor" role in many
disease processes, including cancer.
In hematology, immunology, and blood banking, there is a long tradition
of exploring the possibilities of ultraviolet to produce beneficial changes
in blood components UV has long been known to inactivate viruses while
preserving their ability, to be used as antigens in the preparation of
vaccines (Levinson, 1945). The mechanism proposed being that the viral
genome is more UV-damage sensitive than viral surface antigens. Thus, the
virus can be killed by damage to its nucleic acids while, at the same time,
leaving antigenic surface components (proteins, glycoproteins, and/or fatty
acids) relatively intact.
Most viruses are quite UV-sensitive (Hanson, 1992), however viral inactivation
using conventional photopheresis sufficient for the purposes of the blood
banking industry (six or more logs of killing) is not feasible without
intolerable levels of damage to formed elements in the blood (Fratantoni,
1992; Dodd, 1992).
Benefits: Silver-Max has benefits which avoid the undesirable
effects of "extracorporeal PUVA". Among these are mutations, inhibition
of DNA synthesis, changes in gene expression of various sorts, increased
intracellular Ca+2, the elaboration of cytokines IL1, IL6, and TNF, effects
on prostaglandins, and a variety of cell surface changes (Taylor & Gasparro, 1992; Andreu et al. 1992).
Conclusion: In summation, this process represents a low
cost, nontoxic, pain free way to treat a variety of viral and bacterial
diseases. The key advantage is the low cost in doing so, which could result
in considerable savings to the health industry. Future plans are in preparation
to apply Silver-Max to untreatable conditions such as Alzheimer's, sickle
cell anemia, and E. coli bacteria.
A fuller article with Bibliography about UBIT is available for
reading from The Academy for Future Science at http://www.affs.org
|